Reproductive Health Science Limited (ASX:RHS) is pleased to advise it has signed 3-year exclusive distribution agreements with distributors based in Israel and South Africa, for the sale of its lead product EmbryoCellect(TM).
Rhinomed Ltd (ASX:RNO) is pleased to announce the appointment of Justine Heath as its Chief Operating Officer/Chief Financial Officer effective from today.
Reproductive Health Science Limited (ASX:RHS) ("RHS" or the "Company") announces its fourth quarter cash flow report for the year ending 31 December 2014.
Rhinomed Ltd (ASX:RNO) is encouraged by the strong level of interest in the technology platform from customers and partners both within Australian and overseas. The company is in a strong financial position to take full advantage of the technology platform that has been created over the last 18 months.
Rhinomed Ltd (ASX:RNO) is pleased to announce that it will begin shipping its next generation Turbine technology on February 9th, 2015.
Reproductive Health Science Limited (ASX:RHS) is pleased to advise it has signed a 3-year exclusive distribution agreement with SAR Healthline (P) Ltd for the sale of its lead product EmbryoCellectTM in India, Sri Lanka and Bangladesh.
Rhinomed develops, markets and partners it's internal nasal technology platform into multiple form factors - internal nasal devices, with a focus on unmet needs in sport & exercise, sleep (snoring, sleep quality and sleep apnea), wellness and drug delivery
